The control group was characterized by a lower percentage value of CD83+ Mo-DC with CD200R antigen expression (median 65.87 %, range from 36.21 to 89.05 %; mean 65.78 ± 12.38 %) than individuals with laryngeal cancer (median 79.86 %, range from 29.03 to 95.34 %; mean 72.01 ± 16.98 %), but the statistical significance was also not revealed (p = 0.277, Fig. 9). This evidence concerns the gene CD83 and laryngeal carcinoma.